Bioversys

Basel, Switzerland. January 07, 2021, 2pm CEST BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today that Marc Gitzinger, Chief Executive Officer at BioVersys, will present a company overview

Basel, Switzerland. November 3, 2021, 9am CEST BioVersys AG doses first subjects in multiple ascending dose and renal impairment Phase 1 clinical trials with BV100 BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and

Basel, Switzerland. August 24, 2021, 9am CEST BioVersys AG appoints Dr. William Jenkins as special advisor and board member elect BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today

Basel, Switzerland. July 6, 2021, 9am CEST BioVersys presents update on its innovative antimicrobial pipeline with three oral and six poster presentations at ECCMID, July 9-12, 2021 BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance

Basel, Switzerland. June 30, 2021, 9am CEST BioVersys adds experienced personnel to key management positions. BioVersys AG is further strengthening its management team with the appointments of Dr. Stephan Amrein as Head of CMC and Dr. Isabelle Andrieux-Meyer as Medical Director. Stephan joins BioVersys with 17 years of experience in pharmaceutical product development.  Most recently,

Basel, Switzerland. June 1, 2021, 9am CET CARB-X funds BioVersys up to US$ 15.34 million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics, targeting difficult to treat ESKAPE pathogens BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with

Basel, Switzerland. May 18, 2021, 9am CET BioVersys is strengthening its executive management team with the appointment of Martin Bott as Chief Financial Officer as of May 17, 2021. Martin will lead financial operations at BioVersys and support the company in its continued evolution as one of the leading, clinical stage biotech companies developing novel

Basel, Switzerland. April 14, 2021. 09:00 CEST European Investment Bank and BioVersys sign a financing agreement of up to €20 million to facilitate the development of new treatments against life-threatening resistant bacterial infections. The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research

Basel, Switzerland. Februar 25, 2021. 09:00 CEST BioVersys and consortium partners TASK Foundation and GSK have been awarded 2.7 million Euro from European and Developing Countries Trial Partnership (EDCTP) for the further development of BVL-GSK098 with ethionamide in a Phase 2a tuberculosis clinical trial study. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focusing